Translating Data From Trial to Practice

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Updates and Perspectives in Diabetic Dyslipidemia

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

PCSK9 Inhibitors Post-CVOTs

Preventing Thrombotic Complications in ACS: State of the Art

NOACs for Cancer-Associated Thrombosis:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Diabetes and Dyslipidemia

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

The Safety and Efficacy of Full vs

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Select Topics in Cardiovascular Medicine

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Can Primary Care Physicians Take the Lead in Combating Obesity?

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

What Has Been Tried and What Is True?

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Efficacy and Safety of Edoxaban in Patients With AF and HF

CV Risk Doesn't End in the Cath Lab

Antithrombotic Protection in CAD and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

A Better Solution For Cancer Patients With VTE?

Five Things You Need to Know About Secondary Prevention Post-ACS

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Aspirin in Cardioprevention:

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

CV Risk Doesn't End in the Cath Lab

Aspirin and Cardioprevention in 2018

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Updates in Anticoagulation: Key Sessions at ESC 2017

Managing Pulmonary Embolism Posthospital Discharge

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Flow of Patients Through the Trial

2015 EASD In Review: CV Risk management in t2dm

Omega-3s vs Pure EPA in Clinical Practice

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

PCSK9 Inhibitors and Real-World Evidence

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

The Power of As-Treated Analyses

Presentation transcript:

Translating Data From Trial to Practice

Diabetes and the Cardiovascular Risk Spectrum

THEMIS Study Design

Moving Down the Spectrum of Vascular Risk

THEMIS History of Disease at Baseline

THEMIS Primary Results

THEMIS: Efficacy Endpoints Over 3 Years (ITT Population)

THEMIS: Prespecified Hierarchical Outcomes Over 3 Years (mITT Population)

THEMIS Efficacy Analysis: Prespecified Subgroups

Primary Efficacy Endpoint: Time Since PCI THEMIS-PCI Post Hoc Analysis

THEMIS: Safety Outcomes

THEMIS-PCI: Prespecified Subgroup Analysis

THEMIS-PCI: Prespecified Subgroup Analysis (cont)

THEMIS-PCI: Safety Outcomes

THEMIS: Events Prevented or Caused for 1000 Patients Treated With Ticagrelor + Aspirin

Identifying High-Risk Patients…

MI Is a Main Risk Driver SWEDEHEART Study

Similarities Between PEGASUS and THEMIS: Treatment Discontinuations

RCT vs On-Treatment Analysis

THEMIS-PCI On-Treatment Analysis Results

Whom Do You Treat?

How to Treat Non-PCI Patients

Applying CHARISMA to THEMIS-like Patients

Applying COMPASS to THEMIS-like Patients

Conclusions

Abbreviations

Abbreviations (cont)